陈宝安/Baoan Chen
教授/Professor 东南大学附属中大医院
联系电话： 办公时间：周一至周五(Weekdays)
传 真： 主页网址：http://cba8888.haodf.com/
办公地点：主任办公室 电子邮箱：cba8888@hotmail.com
通讯地址：东南大学附属中大医院血液科












研究方向



个人简介：
陈宝安，男，主任医师，教授，博士（后）导师，全国著名血液病和肿瘤学专家，江苏省科教兴卫工程（血液病）医学重点学科带头人。现任东南大学附属中大医院血液科学科带头人、骨髓增生异常综合征研究所所长、肿瘤学系主任。兼任中国抗癌协会临床肿瘤学协作专业委员会执行委员、江苏省抗癌协会理事、中华医学会江苏省血液学会副主任委员、中华医学会南京血液学会前主任委员。 1979年毕业于南京铁道医学院医疗系（今东南大学医学院），毕业后先后在南京铁道医学院完成硕士，上海医科大学（今复旦大学上海医学院）完成博士学位，在德国乌尔姆大学血液肿瘤科完成博士后研究工作，美国MD Aderson Cancer Center、加州大学伯克利分校、德国海德堡大学等多所世界著名大学高级访问****。长期从事血液病临床、教学、科研和管理工作，临床擅长血液病疑难重症诊治，具有丰富的临床经验。科研主攻方向为难治性血液病发生机制及其生物标志物研究、造血干细胞移植并发症防治研究和MDS的研究。主持国家自然科学基金5项、参与“973”、“863” 、科技支撑等多项研究项目。累计发表学术论文400余篇，其中SCI收录近百篇，主（参）编著作3部，先后获教育部科技进步二等奖、江苏省科技进步二等奖。国家级课题5项，省部级二等奖3项，培养出硕士86名，博士18名。培养博士后12人。
Professor Baoan Chen(MD/PhD) is a renowned hematologist andoncologist in China. He is the director of Faculty of Oncology of SoutheastUniversity, leader of Department of Hematology of the Affiliated Zhongda Hospitalof Southeast University, head of MDS Research Institute. He got his bachelor’sdegree and master‘s degree in Nanjing Railway Medical College, MD/PhD degree inShanghai Medical University, and completed his post doc. training in Departmentof Hematology and Oncology of ULM University. He is the senior visiting scholarin MD Aderson Cancer Center, UC Berkely, University of Heidelberg and severalworld‘s famous universities. Professor Chen has rich experience in hematologicalmalignancies diagnosis and treatment. His research interests include overcomingmultidrug resistance of cancer, preventing and treating relapse of leukemia afterHSCT and basic and clinical research of MDS.

主要研究方向：
1.肿瘤耐药方面的研究：白血病治疗失败的主要原因之一为多药耐药，在国家自然科学基金资助下，研究发现汉防己甲素是一种非选择性钙离子通道阻滞剂，它能提高化疗药物对白血病细胞的抑制率，且对正常的骨髓细胞无抑制作用。心肌毒副作用低，实验用量临床可以接受；他莫西芬可通过改善膜结构，竟争性抑制膜糖蛋白对化疗药物的转运。二者单独应用均能逆转多药耐药。我们将二者联合应用，发现有明显的协同作用。经专家评定，此方面研究已达到国际先进水平。
2.基因芯片技术的研究：已完成了检测肿瘤微转移的基因芯片的研究，并获得了国家知识产权及发明专利；并进行了蛋白质芯片的研究。

3.阻断肿瘤新生血管的物理原理及生物效应：针对肿瘤血管生成的治疗措施可成为一个新颖抗癌途径。目前此方面的研究主要集中在对肿瘤血管生成因子，和抗内皮细胞增殖和迁移的方面。通过前期研究，发现通过超声空化及空化核的增强效应，直接损伤肿瘤新生血管，并已完成了低功率超声辐射二氧化碳微泡剂致使肿瘤血管栓塞的实验研究。将进一步对动物移植瘤做进一步的研究，并准备进行临床研究，以期建立无创诱导致肿瘤新生血管内皮细胞损伤及阻断肿瘤血液供应的新方法。
4.造血干细胞移植：近年来完成了造血干细胞移植百余例，费用较低，疗效满意，在群过范围内产生了巨大影响。
??????






荣誉奖励


获奖情况：
?陈宝安，许文林，王雪梅，孙新臣，程坚，沈慧玲，敖忠芳，高峰，袁鹏，刘莉洁.
2009 年“多种方法逆转白血病多药耐药的研究及应用”获教育部科技进步二等奖。
?王雪梅，陈宝安，燕红，姜晖. 2011 年“基于纳米生物技术的肿瘤耐药识别与逆转的
研究”获教育部科技进步二等奖。
授权专利：
?王雪梅，张仁云，吕刚，吴春惠，李景源，高峰，程坚，陈宝安，付德刚，李小毛，
关之群. 治疗白血病的靶向磁性纳米药物及制备方法. 专利号：ZL 2005 1 **.1。
?王雪梅，吴春惠，宋敏，李景源，张仁云，吴德洪，燕红，顾忠泽，陈宝安. 有机金
属碳硼烷靶向纳米制剂的制备方法及制成的靶向制剂. 专利号： ZL 2006 1 **.3。




学术成果


主要承担课题（负责人）：
1. 国家自然科学基金面上项目：汉防已甲素和角罗西芬逆转白血病细胞多药耐药的机理研究（编号：**，研究年限：2000.11－2002.12）已结题
2. 南京市重大课题：非清髓造血干细胞移植治疗白血病（编号：YQ0008，研究年限：2001－2004）已结题
3. 江苏省卫生厅科技发展基金：生物疗法在慢粒ASCT体外净化作用（编号：H200344，研究年限：2003－2005）已结题
4. 东南大学中大医院重大课题：非清髓造血干细胞移植治疗血液病（编号：2003YJ02，研究年限：2003－2005）已结题
5. 高等学校博士学科点专项科研基金：共聚合汉防己甲素和化疗药物的磁性纳米四氧化三铁颗粒在逆转恶性血液病多药耐药中的机理研究（编号：，研究年限：2008－2010）已结题
6. 国家自然基金面上项目：共聚合汉防己甲素和化疗药物的磁性纳米四氧化三铁颗粒在逆转恶性血液病多药耐药中的机理研究（编号：**，研究年限：2008－2009）已结题7. 国家自然基金面上项目：磁性纳米四氧化三铁颗粒共聚合柔红霉素和5－溴汉防己甲素逆转恶性血液病多药耐药的机理研究（编号：**，研究年限：2009－2011）已结题8. 国家高技术研究发展计划（863计划）子课题：急性白血病的治疗（研究年限：2009－2011）已结题
9. 国家高技术研究发展计划（863计划）子课题：超灵敏纳米多孔生物传感器件的研究与开发（编号：32007AA022007，研究年限：2009－2011）已结题
10. 国家重点基础研究发展计划（973计划）子课题：基于仿生分子识别的传感与成像方法研究及其系统设计（编号：2010CB732404，研究年限：2009-2015）在研
11. 国家科技支撑计划课题（十一五）子课题：骨髓增生异常综合征的规范化诊断与治疗策略研究（编号：2008BAI61B02，研究年限：2008－2010）已结题
12. 国家自然基金面上项目：化疗药和中药与转铁蛋白纳米载体的设计及逆转白血病耐药的机制研究（编号：**，研究年限：2012－2015）在研
13. 国家高技术研究发展计划（863计划）子课题：针对生物标志物检测的低成本检测系统的研制（编号：2012AA022703，研究年限：2012－2016）在研
14. 国家自然基金面上项目：血小板靶向载药系统的研制及其抗白血病效应的研究（编号：**，研究年限：2014－2017）在研
15. 江苏省科技厅医学重点项目：江苏省复发和难治性白血病的规范化治疗（编号：BL**，研究年限：2014－2017）在研


Selected Research Programs:
National Key Basic Research and Development Program (973 Program): Researchand Systematic Design of Sensing and Imaging Methods Based on BioinspiredMolecular Recognition
(Grant NO.: 2010CB732404, period:2009-2015)
National High Technology Research and Development Program (863Program): A biomarker for the detection of low-cost system. (Grant NO.:2012AA022703, period: 2012-2016)
National Natural Science Foundation of China: Research on Designingof transferrin nanocarriers of chemotherapy drugs and traditional Chinesemedicine and mechanism of leukemia reverasal. (Grant NO.: **, period: 2012-2015)
National Natural Foundation of China: Development of drug deliverysystems containing platelet targeting and research about its anti-leukemiaeffect. (Grant NO.: **, period: 2014-2017)
Key project of Jiangsu Province: standardized treatment of relapsedand refractory leukemia (Grant NO: BL**, period: 2014-2017)


近五年代表性论文：
1.CaiX, Cai X, Wang C, Chen BA*, Hua W, Shen F et al. Antitumor efficacy of DMSA modified Fe3O4 magneticnanoparticles combined with arsenic trioxide and adriamycin in Raji cells. J Biomed Nanotech2014; 10(2): 251-261.
2.ChangH, Wang X, Shiu KK, Zhu Y, Wang J, Li Q, Chen BA* et al. Layer-by-layer assembly of graphene, Au andpoly(toluidine blue O) films sensor for evaluation of oxidative stress of tumorcells elicited by hydrogen peroxide. Biosensors& Bioelectronics 2013; 41: 789-794.
3.ChengJ, Cheng L, Chen BA*, Xia G, Gao C, Song H et al. Effect of magnetic nanoparticles of Fe3O4 and wogonin onthe reversal of multidrug resistance in K562/A02 cell line. Int J Nanomedicine2012; 7: 2843-2852.
4.FangL, Chen BA,Liu S, Wang R, Hu S, Xia G, Chen BA* et al.Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acidon phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. Int JNanomedicine2012; 7: 4109-4118.
5.JiangN, Zhu X, Zhang H, Wang X, Zhou X, Gu J, Chen BA* et al. The relationship between methylenetetrahydrofolatereductase polymorphism and hematological malignancy. Clin Lab2014; 60(5): 767-774.
6.JinN, Malcherek G, Mani J, Zurleit R, Schmitt A, Chen BA et al. Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus. Leuk Lymphoma 2014; 55(5): 1144-1150.
7.LiK, Chen BA*,Xu L, Feng J, Xia G, Cheng J et al.Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine 2013; 8: 1867-1877.
8.LiangG, Li J, Sun B, Li S, Lu L, Wang Y, Chen BA* et al. Deep sequencing reveals complex mechanisms ofmicroRNA deregulation in colorectal cancer. Int J Oncology 2014; 45(2): 603-610.
9.LuX, Zhu A, Cai X, Jia Z, Han W, Ma L, Chen BA* et al. Role of NKG2D in cytokine-induced killer cellsagainst multiple myeloma cells. CancerBio Therapy 2012; 13(8): 623-629.
10.MouY, Hou Y, Chen BA*, Hua Z, Zhang Y, Xie H et al. In vivo migration of dendritic cells labeled with syntheticsuperparamagnetic iron oxide. Int J Nanomedicine 2011; 6: 2633-2640.
11.RenY, Zhang H, Chen BA*, Cheng J, Cai X, Liu R et al. Multifunctional magnetic Fe3O4 nanoparticles combined withchemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine2012; 7: 2261-2269.
12.SongG, Gu L, Li J, Tang Z, Liu H, Chen BA* et al. Serum microRNAexpression profiling predict response to R-CHOP treatment in diffuse large Bcell lymphoma patients. Ann Hematol 2014.e-pub ahead of print 2014/05/27
13.WangC, Cai X, Chen BA*, He Z, Chen Z, Cen J et al. Up-regulation of tissue inhibitor of metalloproteinase-2promotes SHI-1 cell invasion in nude mice. Leuk Lymphoma 2013; 54(12): 2707-2711.
14.WangC, Zhang H, Chen Y, Shi F, Chen BA*. Gambogic acid-loaded magnetic Fe(3)O(4)nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migrationby inactivating transcription factor ETS1. Int J Nanomedicine2012; 7: 781-787.
15.Wang F, Zhang W, Guo L, Bao W,Jin N, Liu R, Chen BA* et al. Gambogic acid suppresses hypoxia-inducedhypoxia-inducible factor-1alpha /vascular endothelial growth factor expressionvia inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein ofrapamycin pathway in multiple myeloma cells. Cancer Sci2014. e-pub ahead of print 2014/06/04.
16.WangL, Zhang H, Chen BA*, Xia G, Wang S, Cheng J et al. Effect of magnetic nanoparticleson apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine2012; 7: 789-798.
17.WangX, Wang X, Gao S, Zheng Y, Tang M, ChenBA*. A solid-state electrochemiluminescencesensing platform for detection of catechol based on novel luminescent compositenanofibers. Talanta 2013; 107: 127-132.
18.WenJ, Jiang S, Chen Z, Zhao W, Yi Y, Yang R, Chen BA* et al. Apoptosis selectively induced in BEL-7402 cells byfolic acid-modified magnetic nanoparticles combined with 100 Hz magnetic field.Int J Nanomedicine2014; 9: 2043-2050.
19.XuP, Chen BA*,Feng J, Cheng L, Xia G, Li Y et al.Polymorphisms in XPC provide prognostic information in acute myeloid leukemia. Int J Hematology 2012; 96(4): 450-460.
20.XuP, Li J, Chen BA*, Wang X, Cai X, Jiang H et al. The real-time neurotoxicityanalysis of Fe3O4 nanoparticles combined with daunorubicin for rat brain invivo. J Biomed Nanotechnology 2012; 8(3): 417-423.
21.XuP, Li J, Shi L, Selke M, Chen BA*, Wang X. Synergetic effect of functionalcadmium-tellurium quantum dots conjugated with gambogic acid for HepG2cell-labeling and proliferation inhibition. Int J Nanomedicine2013; 8: 3729-3736.
22.XuY, Wang Y, Li XM, Huang Q, Chen W, Liu R, Chen BA* et al. Study on the release of fenofibrate nanosuspension invitro and its correlation with in situ intestinal and in vivo absorptionkinetics in rats. Drug Dev Indus Pharmacy2014; 40(7): 972-979.
23.YangZ, Chen BA*,Pei X, Shangguan F. Multiplex analysis of tumor multidrug-resistance genesexpression with photonic suspension array. TheAnalyst 2012; 137(14): 3343-3348.
24.ZhangH, Wang C, Chen BA*, Wang X. Daunorubicin-TiO2 nanocompositesas a "smart" pH-responsive drug delivery system. Int J Nanomedicine2012; 7: 235-242.
25.ZhongY, Wu J, Chen BA*, Ma R, Cao H, Wang Z et al. Investigation and analysis of single nucleotidepolymorphisms in Janus kinase/signal transducer and activator of transcriptiongenes with leukemia. Leuk Lymphoma 2012; 53(6): 1216-1221.
26. Zhang HJ, Chen BA*,Jiang H, Wang CL, Wang HP, Wang XM. A strategy for ZnO nanorod mediatedmulti-mode cancer treatment. Biomaterials. 2011; 32(7):1906-14.
27. Chen BA*, Wu WW, WangXM. Magnetic Iron Oxide Nanoparticles for Tumor-targeted Therapy. Curr CancerDrug Targets 2011; 11(2):184-9.
28. Zhang HJ, Jiang H, Sun FF, Wang HP, Zhao J, Chen BA*, Wang XM. Rapid diagnosis of multidrug resistance in cancerby electrochemical sensor based on carbon nanotubes-drug supramolecularnanocomposites. Biosens Bioelectron. 2011; 26(7):3361-6.
29. Song M, Zhang RR, Dai YY, Gao F, Chi H, Lv G, Chen BA,* Wang XM. The in vitro inhibitionof multidrug resistance by combined nanoparticulate titanium dioxide and UV irradition.Biomaterials. 2006; 27(23):4230-8.
30. Chen BA*, Yin L, ChengJ, Ding JH, Gao C, Sun YY, Zhao G, Wang J, Bao W, Xia GH, Gao F, Wang XM.Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1 -propanol andtetrandrine on the reversion of multidrug resistance in K562/A02 cells.Hematology. 2011; 16(1):24-30.
31. Wu WW, Chen BA*, ChengJ, Wang J, Xu WL, Liu LJ, Xia GH, Wei H, Wang XM, Yang M, Yang L, Zhang Y, XuC, Li J. Biocompatibility of Fe3O4/DNR magnetic nanoparticles inthe treatmentof hematologic malignancies. Int J Nanomedicine. 2010; 5:1079-84.
32. Wang J, Chen Y, Chen BA*,Ding JH, Xia GH, Gao C, Cheng J, Jin N, Zhou Y, Li XM, Tang M, Wang XM.Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticlesin mice. Int J Nanomedicine. 2010; 5:861-6.
33. Chen BA*, Mao P, ChengJ, Gao F, Xia GH, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Chen W, Chen N, LiuLJ, Li XM, Wang XM. Reversal of multidrug resistance by magnetic Fe3O4nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector inleukemia cells. Int J Nanomedicine. 2010; 5:437-4.
34. Chen BA*, Jin N, WangJ, Ding JH, Gao C, Cheng J, Xia GH, Gao F, Zhou Y, Chen Y, Zhou G, Li XM, ZhangY, Tang M, Wang XM. The effect of magnetic nanoparticles of Fe(3)O(4) on immunefunction in normal ICR mice. Int J Nanomedicine. 2010; 5:593-9.
35. Zhang HJ, Jiang H, Wang XM, Chen BA*. Reversion of multidrugresistance in tumor by biocompatible nanomaterials. Mini Rev Med Chem. 2010;10(8):737-45.
36. Zhong YJ, Chen BA*,Feng JF, Cheng L, Li Y, Qian J, Ding JH, Gao F, Xia GH, Chen N, Lu Z. Theassociations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomesin patients with acute myeloid leukemia. Leuk Lymphoma. 2010; 51(6):1115-20.
37. Zhu XL, Zhang HJ, Lin Y, Chen P, Min J, Wang Z, Xiao W, Chen BA*. Mechanisms of gambogicacid-induced apoptosis in non-small cell lung cancer cells in relation to transferrinreceptors. J Chemother. 2009; 21(6):666-72.
38. Pei XP, Chen BA*, LiL, Gao F, Jiang Z. Multiplex tumor marker detection with new chemiluminescentimmunoassay based on silica colloidal crystal beads. Analyst. 2010; 135(1):177-81.
39. Chen BA*, Liang YQ, WuWW, Cheng J, Xia GH, Gao F, Ding JH, Gao C, Shao Z, Li G, Chen W, Xu WL, SunXC, Liu LJ, Li XM, Wang XM. Synergistic effect of magnetic nanoparticles ofFe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine.2009; 4:251-9.
40. Cheng J, Wu WW, Chen BA*,Gao F, Xu WL, Gao C, Ding JH, Sun YY, Song HH, Bao W, Sun XC, Xu C, Chen W,Chen N, Liu LJ, Xia GH, Li XM, Wang XM. Effect of magnetic nanoparticles ofFe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02leukemic cells. Int J Nanomedicine. 2009; 4:209-16.
41. Pei XP, Zhao Y, Zhao X, Xu H, Chen BA*, Gu ZZ. Multiplex chemiluminescent immunoassay based onsilica colloidal crystal beads. J N N. 2009; 9(11):6320-5.
42. Sun N, Sun XC, Chen BA*,Cheng H, Feng JF, Cheng L, Lu ZH. MRP2 and GSTP1 polymorphisms and chemotherapyresponse in advanced non-small cell lung cancer. Cancer Chemoth Pharm. 2010;65(3):437-46.
43. Li Y, Deng Z, Xuan H, Zhu J, Ding B, Liu X, Chen BA*. Prolonged chronic phase in chronic myelogenous leukemiaafter homoharringtonine therapy. Chin Med J (Engl). 2009;122(12):1413-7.
44. Jiang Z, Chen BA*, XiaGH, Wu Q, Zhang Y, Hong T, Zhang W, Cheng J, Gao F, Liu LJ, Li XM, Wang XM. Thereversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin onSKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009; 4:107-14.
45. Chen BA*, Cheng J, WuYN, Gao F, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Sun XC, Cheng H, Li G, ChenW, Chen N, Liu LJ, Li XM, Wang XM. Reversal of multidrug resistance by magneticFe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine inxenograft nude-mice. Int J Nanomedicine. 2009; 4:73-8.
46. Chen BA*, Cheng J,Shen MF, Gao F, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Sun XC, Cheng H, Li G,Chen W, Chen N, Liu LJ, Li XM, Wang XM. Magnetic nanoparticle of Fe3O4 and5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin inleukemia cells. Int J Nanomedicine. 2009; 4:65-71.
47. Chen BA*, Dai YY, WangXM, Zhang R, Xu WL, Shen HL, Gao F, Sun Q, Deng X, Ding JH, Gao C, Sun Y, ChengJ, Wang J, Zhao G, Chen N. Synergistic effect of the combination of nanoparticulateFe3O4 and Au with daunomycin on K562/A02 cells. Int J Nanomedicine. 2008;3(3):343-50.
48. Chen BA*, Sun Q, WangXM, Gao F, Dai YY, Yin Y, Ding JH, Gao C, Cheng J, Li JY, Sun XC, Chen N, XuWL, Shen HL, Liu D. Reversal in multidrug resistance by magnetic nanoparticleof Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. IntJ Nanomedicine. 2008; 3(2):277-86.